China’s Personalized mRNA Cancer Vaccine Race Accelerates After Moderna and Merck’s Phase 3 Melanoma Success
The personalized cancer vaccine field has reached a major inflection point. Moderna and Merck announced on August 19, 2026 that their Phase 3 INTerpath-001 trial of intismeran autogene (V940/mRNA-4157) plus KEYTRUDA (pembrolizumab) met both its primary…